All In Biotech

Drug Trial Radar · NCT05972629

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

A Phase 1/Phase 2, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of SAR444836, an Adeno-associated Viral Vector-mediated Gene Transfer of Human Phenylalanine Hydroxylase, in Adult Participants With Phenylketonuria

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 7, 2023

Primary completion

Apr 2, 2030

Study completion Apr 2, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with phenylketonuria (PKU) on a chronic, stable diet. The purpose of the study is to evaluate the safety and efficacy of SAR444836 in reducing phenylalanine (Phe) levels and in the elimination of a Phe restricted diet. Participants will receive a one-time intravenous (IV) administration of SAR444836. The study is constituted of 2 separate parts: a dose escalation part, and a dose expansion part where subsequent participants will be administered a safe and effective dose level identified during the dose escalation part. In both study parts, clinical and laboratory assessments will be collected to: a) assess the incidence of adverse events, and b) evaluate the effect of SAR444836 on reductions in blood Phe levels and maintenance of these Phe levels after elimination of a Phe restricted diet. The study duration will be for a minimum duration of 5 years following SAR444836 administration, for each participant and includes a 6-week screening phase, a 96-week treatment follow-up period after SAR444836 administration, followed by an additional 3 years of long-term safety (and efficacy) monitoring. There will be a total of 47 study visits. Many study visits may occur as remote visits and be performed by a qualified in-home service provider. Actual study duration for an individual participant may be longer than 5 years due to the administration of SAR444836 to participants in Stage 1A in a serial fashion, the duration of the screening period, and/or other factors such as delays in scheduling study visits.

Conditions

  • Phenylketonuria

Interventions

  • SAR444836Drug

    Infusion pump, intravenous infusion (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From Baseline to Week 260

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California San Francisco- Site Number : 8400007

    San Francisco, California

  • Children's Hospital IMD Clinic- Site Number : 8400015

    Aurora, Colorado

  • University of Florida-Genetics- Site Number : 8400010

    Gainesville, Florida

  • UHCMC- Site Number : 8400014

    Cleveland, Ohio

  • UPMC Children's Hospital of Pittsburgh-4401 Penn Ave- Site Number : 8400018

    Pittsburgh, Pennsylvania

  • Medical University of SC- Site Number : 8400004

    Charleston, South Carolina

  • University of Texas- Site Number : 8400002

    Houston, Texas

  • Investigational Site Number : 0320002

    Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

  • Hospital de Clinicas de Porto Alegre - HCPA- Site Number : 0760001

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 3760001

    Tel HaShomer, Israel

  • Investigational Site Number : 7920001

    Ankara, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.